{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:48:49Z","timestamp":1792547329479,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:p>\n                    This study investigates the difference in overall survival rates after transurethral resection of bladder tumor between solitary and multiple bladder cancers, aiming to provide guidance for clinical practitioners. A retrospective analysis was conducted on 133 patients with bladder cancer who underwent transurethral resection of bladder tumor from April 2017 to October 2023, of which 112 patients had complete clinical and follow-up data. Clinical and follow-up data were collected, and the overall survival rates after surgery were compared between solitary and multiple bladder cancers. In this study, the recurrence rate after transurethral resection of bladder tumor was 23.21% (26\/112), and the overall survival rate was 80.36% (90\/112). The overall survival rate after transurethral resection of bladder tumor was 92.11% (35\/38) in the solitary bladder cancer group and 74.32% (55\/74) in the multiple bladder cancer group, with a statistically significant difference between the 2 groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.025). The proportion of high-grade pathology was 7.89% (3\/38) in the solitary bladder cancer group and 25.68% (19\/74) in the multiple bladder cancer group after transurethral resection of bladder tumor, with a statistically significant difference between the 2 groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.025). The mean tumor diameter after transurethral resection of bladder tumor was 2.76\u2005\u00b1\u20051.66\u2005cm in the solitary bladder cancer group and 4.04\u2005\u00b1\u20053.17\u2005cm in the multiple bladder cancer group, with a statistically significant difference between the 2 groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.023). Univariate and multivariate regression analyses revealed that the number of bladder tumors is a risk factor for overall survival after bladder cancer surgery (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004). Multiple bladder cancers have a higher pathological grade, larger tumor diameter, and poorer prognosis after transurethral resection of bladder tumor compared to solitary bladder cancers. The number of bladder tumors is an independent risk factor for overall survival after bladder cancer surgery.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000040314","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T16:03:10Z","timestamp":1730736190000},"page":"e40314","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of prognosis after transurethral resection of bladder tumor between solitary and multiple bladder cancers"],"prefix":"10.1097","volume":"103","author":[{"given":"Mingxin","family":"Diao","sequence":"first","affiliation":[{"name":"Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihui","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunji","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5900-4191","authenticated-orcid":false,"given":"Yaming","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital-Miyun Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260804","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature.","volume":"21","author":"Botteman","year":"2003","journal-title":"PharmacoEcon"},{"key":"R2-20260804","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/ijc.34228","article-title":"The causal association between smoking, alcohol consumption and risk of bladder cancer: a univariable and multivariable Mendelian randomization study.","volume":"151","author":"Xiong","year":"2022","journal-title":"Int J Cancer"},{"key":"R3-20260804","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review.","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"R4-20260804","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12967-023-04151-1","article-title":"The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer.","volume":"21","author":"Long","year":"2023","journal-title":"J Transl Med"},{"key":"R5-20260804","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12944-021-01554-1","article-title":"Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.","volume":"20","author":"Zhu","year":"2021","journal-title":"Lipids Health Dis"},{"key":"R6-20260804","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer.","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"R7-20260804","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer.","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"R8-20260804","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines.","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"R9-20260804","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the international bladder cancer group.","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R10-20260804","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice.","volume":"20","author":"van Hoogstraten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R11-20260804","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer.","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R12-20260804","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/medicina57080749","article-title":"Bladder cancer: current challenges and future directions.","volume":"57","author":"Dobruch","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"R13-20260804","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.euo.2021.01.004","article-title":"Perioperative immunotherapy in muscle-invasive bladder cancer.","volume":"4","author":"Tripathi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R14-20260804","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/MOU.0000000000000600","article-title":"Perioperative systemic therapy for bladder cancer.","volume":"29","author":"Eulitt","year":"2019","journal-title":"Curr Opin Urol"},{"key":"R15-20260804","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel therapies for high-risk non-muscle invasive bladder cancer.","volume":"25","author":"Al Hussein Al Awamlh","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"R16-20260804","first-page":"100296","article-title":"Role of immunotherapy in bladder cancer.","volume":"26","author":"Rhea","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"R17-20260804","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"Nccn guidelines\u00ae insights: bladder cancer, version 2.2022.","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R18-20260804","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020.","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R19-20260804","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer.","volume":"163","author":"Mill\u00e1n-Rodr\u00edguez","year":"2000","journal-title":"J Urol"},{"key":"R20-20260804","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1442-2042.2007.01890.x","article-title":"Bladder sparing approach for initial t1g3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.","volume":"14","author":"Denzinger","year":"2007","journal-title":"Int J Urol"},{"key":"R21-20260804","doi-asserted-by":"crossref","first-page":"180","DOI":"10.23736\/S2724-6051.22.04953-9","article-title":"Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG.","volume":"75","author":"Contieri","year":"2023","journal-title":"Minerva Urol Nephrol"},{"key":"R22-20260804","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81\u2009mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27\u2005mg in superficial bladder cancer.","volume":"89","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"R23-20260804","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOU.0b013e328356ac20","article-title":"Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer.","volume":"22","author":"Rodr\u00edguez Faba","year":"2012","journal-title":"Curr Opin Urol"},{"key":"R24-20260804","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after tur in stage ta t1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"R25-20260804","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ijc.23856","article-title":"The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses.","volume":"124","author":"Hemelt","year":"2009","journal-title":"Int J Cancer"},{"key":"R26-20260804","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ije\/dyw044","article-title":"Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies.","volume":"45","author":"van Osch","year":"2016","journal-title":"Int J Epidemiol"},{"key":"R27-20260804","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/03009734.2011.650797","article-title":"Urothelial bladder carcinoma in young patients is characterized by a relatively good prognosis.","volume":"117","author":"Poletajew","year":"2012","journal-title":"Ups J Med Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000040314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:01:55Z","timestamp":1785841315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000040314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":27,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040314","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}